The troll known here for a decade under a variety of names - fstout57, rickarooski, mauihope, smelky, both quadhole and quadholes, among other aliases - now has a dysfunctional new trick that he's deployed in recent weeks. When he eventually sobers up and realizes that he posted something that revealed his stunning ignorance of, say, SEC reporting requirements or quarterly earning reports or...pretty much everything else - and when comments from other posters correct and shatter his dunderheaded posts, he now reaches back in time and deletes his original, ignorant posts. These acts also delete the corrective comments, and he can pretend that it all never happened. But, as we told him years ago, literally everyone here is smarter than he is, so...we know. We know.
That was great! Clearly, that was one of those Back to the Future anniversary posts - in which the decade-long troll who uses the aliases rickarooski/fsout57/quadhole and quadholes/smelky/mauihope and others - returns to his original alias. Still as nutty as ever. And, as always, 10 is 10. What a jester that guy is!
wInner123: You might find it helpful to know that fstout57 is just one of the many aliases employed here for nearly a decade by the troll also known as rickarooski, mauihope, smelky, both quadhole and quadholes, and many others. He, alone, repeatedly has tried to undermine this unusually helpful and rational Yahoo message board, but he has failed because virtually everyone has virtually all of his aliases on ignore (which is why he keeps inventing new aliases.) He shows up when he happens to be right about the short-term direction of the stock; he disappears for weeks or months when he happens to be wrong. He does no research. He does not understand biotechs or their common stages of life. He does not comprehend SEC reporting regulations. He does not respond to factual rebuttals of his stream-of-consciousness, meandering theories. And he certainly does not buy or sell this stock. He's just...a troll, and not a particularly good one.
If any single theme is emerging from today's conference call, it is this: In CEO Clay Siegall's words, the company is "very excited" about its 15 upcoming catalysts, most with target dates coming later this year and during the first half of next year. (See the press release for the full list.)
Many of those announcements will come before and during the Dec. 5-8 ASH conference. Siegall repeatedly highlighted the ASH abstracts that will be released next week and he repeatedly used the word "excited," which, in the past, always has previewed extremely good news.
quadhole, eh? Alias created on June 29; 30 posts on various boards in the last 24 hours; many posts attacking the Bakers; and complete ignorance regarding SEC reporting regulations. Looks like the troll known here as rickarooski/fsout/mauihope/smelky/etc. has yet another new personality.
OT: So, not content with the 10 or so aliases you already have, now you have two versions of this one - quadhole and quadholes. Really, dude. See your physician.
There also was a good bit of upbeat chatter about this, which eventually could be the Big One: Report interim phase 1 clinical data from SGN-LIV1A, an ADC targeted to LIV-1 in development for metastatic breast cancer, at the San Antonio Breast Cancer Symposium being held December 8-12, 2015 in San Antonio, TX.
You really have to wonder what they're thinking, what they're up to, and how deep their research was - or wasn't. From a Seeking Alpha summary of the Goldman Sachs report:
- Price target: $33 (implied downside 27%).Firm says Adcetris upside through label expansion is already baked into the stock. Says SGEN's pipeline outlook is unclear.
- Among 15 analysts, Goldman is the only firm with a Sell rating on SGEN. Street low, prior to Goldman's initiation, was $40.50 (Cowen's Dr. Boris Peaker).
- On Oct. 30, Needham ($60 price target) said it expects continued growth from Adcetris as it penetrates this market and expands its label further in the coming years, and noted SGEN is making progress with proprietary pipeline of antibody drug conjugates (ADCs). "We look for significant updates on these and other programs at ASH in December. We continue to view SGEN as one of the few mid-cap biotech companies with the ability to grow into a sustainable large cap drug developer."
Stepping back a bit, two thoughts: 1. Beginning this last buy of 329,358 shares a few hours after Goldman Sachs, obviously with an agenda, commissioned a hit job on SGEN, Baker clearly was giving Goldman and its "objective" analyst a raised middle finger. 2. Maintaining their position in SGEN is one thing. Increasing it modestly from time to time is another thing. But for the Bakers, board members privy to all sorts of inside information, to so constantly and massively increase their stake - now standing at 26.8 percent - is really quite something else. Conclusion: This is as close to a sure thing, imo, as one can get in biotech.
Well, they sure had our butts covered during this offering. I've been around awhile and I've never seen a secondary - for this company or any other - that was so carefully structured and handled for the benefit of all existing shareholders.
And, another hyperactive flurry of six posts within 18 minutes from the troll known as the now self-admitted multi-alias quadhole/fsout/rickarooski/smelky/mauihope. (His "last comment" lasted only four minutes until the next comment.) Poor fellow. Over and out, dude. We're on to you again.
fstout/ricky/quadhole/quadholes/mauihope/etc: Briefly taking you off ignore to make clear that 1. My sells and repurchases were rare. 2. I never bashed your or anyone else for selling. 3. I frequently bashed you for being an absolute, total moron and a multi-aliased troll.
The writer of this story is not very sophisticated, but you get the general idea. From the Puget Sound Business Journal:
Seattle Genetics is currently in the midst of its largest-ever financing round.
The Bothell-based biotech company announced Monday that it was increasing its $480 million public stock offering — announced last week— to $552 million, by exercising its over-allotment option.Seattle Genetics CEO Clay Siegall said the company increased its offering after getting a huge amount of interest from investors.
He also said Seattle Genetics will use the proceeds of the offering not just on development of its drug pipeline and expanding the use of its flagship cancer drug Adcetris but also to continuing to grow the company, in both people and infrastructure.
He expects Seattle Genetics will hire roughly 100 people per year for the next five or so years, which would bring the company's headcount to about 1,300 by 2020. To accommodate that growth, Seattle Genetics is also eying other spaces to lease in the Canyon Park area of Bothell, where the company is currently located at 21823 30th Dr. S.E.
"We're busting at the seams," Siegall said. "I don't want to step too far ahead, but we're going to have to have some other buildings as well."
Seattle Genetics, founded in 1998, is one of the Puget Sound region's longest-standing biotech companies, though it is not yet profitable. In the second quarter of this year, the company posted a $47.5 million loss in on revenue of $77 million. Of that revenue, $55.1 million came from sales of Adcetris.
Siegall said a lack of profitability is not a concern moving forward with plans to expand.
"Seattle Genetics could be a profitable company now if that was our immediate short-term goal," he said. "But at this point, it would be to put profitability as the most important thing today, because we are still building."
It's not uncommon for biotech companies to take a long time to turn a profit....
Every now and then I take you and the rest of your aliases off ignore just to remind myself how profoundly stupid you are. With 100+ percent of this stock owned by institutions and more than 1 million shares traded every day, you actually think that anything you or I or anyone else posts on a Yahoo message board - read by maybe 10 people - influences the share price. Never forget: "Ten is ten."
It's all so silly. A candidate says, "I will do this and I will do that and I will do this other thing." And the sheer truth of the matter is that he or she won't and can't do any of it without congressional agreement and, these days, Congress can't even agree that this is September. So, yes. A tweet by one candidate or a statement by another or a downgrade by a never-heard-of-it investment house...it's all just noise. This, too, shall pass.
wInner123, I know I violated my own policy, and I'll try not to again, because each response just encourages him and he sticks around until the stock does better or his meds kick in or he gets bored. But it's truly best to keep fstout and all his other aliases - rickarooski, mauihope, smelky, both quadhole and quadholes, and the others as they develop - on ignore. He's just another garden variety troll - more inventive than most, also more unbalanced and transparent. If we keep responding, we risk turning this into just another useless Yahoo board. I'm going to be more disciplined about this myself.
A perceptive piece from MarketWatch (including an SGEN buy recommendation near the bottom):
If you missed out on the enormous run in biotechnology stocks this past year, Hillary Clinton just gave you a second chance.
Since Clinton’s infamous Sept. 21 tweet attacking drug companies for “price gouging,” biotech investors have lost an astonishing $132 billion. I’m pretty sure I know what they think of Hillary.
Many biotech stocks fell 20% to 35% or more in a few trading days, as selling turned panicky Monday. The iShares Nasdaq Biotechnology ETF IBB, +1.90% has declined to where it traded last November.
“I haven’t seen it this bad in years,” says Ron Garren, a medical doctor and oncologist who writes the biotech stock letter Biotech Insight.
“It’s outright fear and panic,” says BioShares Funds portfolio manager Paul Yook, who provided the sector loss estimate cited above. “I have been on the phone all morning with panicked investors. Everyone is asking, ‘How much lower can it go? Do we bail?’ ”
The answers: No one knows how much lower it can go. But don’t bail. This is a better time to buy than sell, say several biotech experts.
The bottom line here is that while drug pricing will hang around as a presidential campaign issue, any Washington, D.C., reform that hurts biotech companies will be far off, if it happens at all. And that is unlikely. So while the issue will create more volatility, it will also devolve into background noise....
In the current weakness, Thornburg Value Fund’s Browne favors Gilead Sciences GILD, +1.74% and Seattle Genetics SGEN, +1.93% two companies the fund owns. McCamant suggests Incyte INCY, +5.44% and Ziopharm Oncology ZIOP, +2.63% Garren, who follows small-cap companies, likes Oncothyreon ONTY, +0.70% and Array BioPharma ARRY, -1.05%
For the entire piece, Google: Six ways to profit from Hillary Clinton’s $132 billion tweet
There's probably a good reason why SGEN waited until the market closed before releasing its comprehensive, probably-good-for-the-stock ASH presentation press release and presentation schedule just now but...I can't think of one.
From what I can see, biotech in general and SGEN in particular are more suceptible to Wall Street shenanigans than most other investments. You can see the ying-yang and string-pulling several times a week - up for no perceptible reason, down for no perceptible reason. Just a lot of trading activity that generates commissions and nothing much else.
As to this week's events, we've seen this before right after the Bakers make a large buy. Repeating my theory on that: Some of the trading interest surrounding SGEN is based on it being an obvious takeover candidate (now, later, eventually, whenever). The Bakers are on the board and are core insiders. Insiders are not allowed to trade if they hold key information not available to the general public. Hence, a major buy by the Bakers suggests that no takeover offer currently is on the SGEN table or is under consideration. So, shorts and potential sellers are relieved (for a little while) of the worry that a high-premium takeover will slap them upside the head. And they trade accordingly.